Orchid Pharma Posts Consolidated Net Profit Of ₹28.59 Crore In Q2
Mumbai: Orchid Pharma announced its financial results for the second quarter of the 2026-27 fiscal year on Friday, November 14, 2026. Financial Performance Consolidated revenue from operations stood at ₹341.27 crore for the quarter, marking an increase compared to ₹298.46 crore in the same period last year. Total consolidated income reached ₹359.02 crore, up from ₹310.10 crore recorded in the…
Mumbai: Orchid Pharma reported a consolidated net profit of ₹28.59 crore in the second quarter of its 2026-27 fiscal year, according to the company's financial results released on November 14, 2026. The quarter saw a significant rise in consolidated revenue from operations, reaching ₹341.27 crore, up from ₹298.46 crore in the same period last year.
Overall income for the quarter also increased to ₹359.02 crore, compared to ₹310.10 crore in the previous quarter. Natco Pharma, meanwhile, announced a sharp decline in its Q2 earnings as profit plummeted 61% to ₹202.6 crore, with revenue falling by 29% and expenses rising.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
